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Abstract
Background: Chronic inflammation and increased oxidative stress significantly contribute in developing coronary
artery disease (CAD). Hence, antioxidant supplementation might be an appropriate approach to decrease the
incidence of CAD. This systematic review and meta-analysis was aimed to determine the effects of coenzyme Q10
(CoQ10) supplementation on lipid profile, as one of the major triggers for CAD, among patients diagnosed with
coronary artery disease.
Methods: EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science were searched for studies prior to May
20th, 2018. Cochrane Collaboration risk of bias tool was applied to assess the methodological quality of included
trials. I-square and Q-tests were used to measure the existing heterogeneity across included studies. Considering
heterogeneity among studies, fixed- or random-effect models were applied to pool standardized mean differences
(SMD) as overall effect size.
Results: A total of eight trials (267 participants in the intervention group and 259 in placebo group) were included
in the current meta-analysis. The findings showed that taking CoQ10 by patients with CAD significantly decreased
total-cholesterol (SMD -1.07; 95% CI, − 1.94, − 0.21, P = 0.01) and increased HDL-cholesterol levels (SMD 1.30; 95% CI,
0.20, 2.41, P = 0.02). We found no significant effects of CoQ10 supplementation on LDL-cholesterol (SMD -0.37; 95%
CI, − 0.87, 0.13, P = 0.14), lipoprotein (a) [Lp(a)] levels (SMD -1.12; 95% CI, − 2.84, 0.61, P = 0.20) and triglycerides
levels (SMD 0.01; 95% CI, − 0.22, 0.24, P = 0.94).
Conclusions: This meta-analysis demonstrated the promising effects of CoQ10 supplementation on lowering lipid
levels among patients with CAD, though it did not affect triglycerides, LDL-cholesterol and Lp(a) levels.
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Background
Dyslipidemia is one of the major risk factor for establish-
ing coronary artery disease (CAD) [1]. Coronary artery
disease and cerebral stroke account for the main causes
of morbidity and mortality among elderly and
middle-aged individuals [2]. Cardiovascular risk factors
are including aging, hyperglycemia and insulin resistance
[3]. In addition, dyslipidemia, mainly hypercholesterol-
emia, high LDL-cholesterol, and low HDL-cholesterol
levels [4] impair mitochondrial function, leading to in-
creased production of free radicals and reactive oxygen
species, and subsequently can result in chronic inflamma-
tion and endothelial dysfunction [5].
The damage of free radicals is proposed to play an im-
portant role in endothelial dysfunction and atherogenesis
[6]. Coenzyme Q10 (CoQ10) is an intracellular antioxi-
dant which prevents senescence and dysfunction caused
by oxidative stress [6]. CoQ10 is commonly used to treat
cardiomyopathy, and heart function has been remarkably
improved following CoQ10 supplementation [7]. CoQ10
deficiency which usually occurs with aging have been
shown to increase the risk of type 2 diabetes mellitus
(T2DM) [8] and cardiovascular disease (CVD) [9]. On
the other hand, there are trials evaluating the effects of
CoQ10 on lipid profiles with inconclusive results. We
have previously shown in a meta-analysis that taking
CoQ10 by patients with metabolic disorders significantly
reduced serum triglycerides levels, yet did not affect
other lipid profiles [10]. In another meta-analysis con-
ducted by Sahebkar et al. [11], CoQ10 supplementation
significantly decreased lipoprotein (a) [Lp(a)] levels
among patients with obesity, T2DM, and CVD, mainly
in those with Lp(a) ≥ 30 mg/dL. However, in another
meta-analysis conducted by Suksomboon et al. [12],
CoQ10 supplementation had no beneficial effects on
lipid profiles or blood pressures among diabetic patients.
Differences in study design, study population’s char-
acteristics, the dosage of CoQ10 used and the dur-
ation of intervention might explain the discrepancies
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Fig. 1 Literature search and review flowchart for selection of studies
Table 1 Characteristics of included studies
Authors (Ref) Publication
year
Sample size
(control/
intervention)
Country/population Intervention (name and daily
dose)
Duration Age (control,
intervention)
Presented
data
Belardinelli et al.
[23]
2006 21/21 Italy/chronic HF CoQ10 100 mg/day 4 weeks 60 ± 8 TC, LDL-C, TG,
HDL-C
Dai Y et al. [24] 2011 28/28 Hong Kong/left ventricular
systolic dysfunction
CoQ10 300 mg/ day 8 weeks 65.9 ± 12.5,
59.9 ± 13.1
TC, LDL-C,
HDL-C, Lp(a)
Mohseni et al.
[15]
2015 26/26 Iran/acute myocardial
infarction
CoQ10 200 mg/day 12 weeks 48.4 ± 0.5,
47.6 ± 0.3
TC, LDL-C, TG,
HDL-C
Mirhashemi et al.
[25]
2016 30/30 Iran/T2DM with CAD CoQ10 100 mg/day 8 weeks 68.9 ± 9.6 Lp(a)
Pourmoghaddas
M et al. [26]
2013 30/32 Iran/statin treated coronary
heart failure patients
CoQ10 200 mg/ day 16 weeks 48.0 ± 8.6,
47.6 ± 8.2
TC, LDL-C
Singh et al. [19] 1999 22/25 India/CAD CoQ10 120 mg/day 4 weeks 50.70 ± 12.5,
54.47 ± 14.6
TC, LDL-C,
HDL-C, Lp(a)
Singh et al. [14] 2003 71/73 India/myocardial infarction CoQ10 120 mg/day 48 weeks 51 ± 9,
51 ± 10
TC, LDL-C, TG,
HDL-C
Sharifi et al. [13] 2017 31/32 Iran/myocardial infarction CoQ10 150 mg/day and L-
carnitine 1200 mg/day
3 months 59 ± 9 TC
CAD coronary artery disease, HDL-C high density lipoprotein-cholesterol, HF heart failure, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein(a), TC total
cholesterol, TG triglycerides, T2DM type 2 diabetes mellitus
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among current evidence. We are aware of no system-
atic review and meta-analysis of randomized con-
trolled trials (RCTs) on the effect of CoQ10
supplementation on lipid profiles in patients with
CAD. This meta-analysis was conducted to
summarize the existing evidence of RCTs to evaluate
the impact of CoQ10 supplementation on lipid pro-
files in patients with CAD.
Methods
PRISMA guideline (the preferred reporting items for
systematic reviews and meta-analyses) was used to de-
sign and implement this meta-analysis.
Search strategy
Two independent authors (RT and MA) systematically
searched online database including EMBASE, Scopus,
PubMed, Cochrane Library, and Web of Science until
20th May 2018. Search words, including Mesh and
text words, were applied as followed; (“chronic heart
failure (CHF)” OR “CAD” OR “myocardial ischemia
(MI)” OR “heart disease (HD)” OR “heart failure, dia-
stolic” OR “CVD” OR “myocardial infarction (MI)”
OR “acute myocardial infarction (AMI)” OR “cardiac
disease (CD)” AND “Q10” OR “coenzyme Q10
(CoQ10)” OR “supplementation” OR “intake” AND
“total cholesterol (TC)” “triglycerides (TG)” OR “low--
density lipoprotein (LDL-cholesterol)” OR “LDL-C”
OR “high-density lipoprotein (HDL-cholesterol)” OR
“HDL-C” OR “lipoprotein(a) (Lp(a))”) to identify the
relevant clinical trials examining the impact of CoQ10
supplementation on lipid profiles. To avoid missing
any citation that had not been captured in the pri-
mary search, the reference lists of the relevant papers
and the pervious article reviews were searched by the
same two researchers (RT, MA). With no time restric-
tion, clinical trials published in English were included
in this meta-analysis.
Study selection
Two investigators (RT, MA) independently screened all
studies, retrieved from the online database and
hand-search, using a two-stage process in order to deter-
mine eligible studies for current meta-analysis. In the
first stage, after reviewing the title and/or abstracts of
the trials, any duplicate and non-relevant trial was re-
moved from further process. Then, in the next stage, the
full texts of related trials were retrieved to determine
whether trials were potentially ideal for this meta-
analysis, considering inclusion and exclusion criteria.
Upon any disagreement, it was resolved by a discussion
among themselves or with a third investigator (ZA or
MV.J).
The following inclusion criteria was used to select eli-
gible clinical trials for the meta-analysis: 1) being a hu-
man original RCT with parallel or crossover method; 2)
study participants were patients diagnosed with heart
diseases; 3) being a placebo-controlled clinical trial
assessing the association between CoQ10 supplementa-
tion and lipid profiles; 4) clinical trials that reported the
mean changes (SD or 95% CI) of the impact of CoQ10
Fig. 2 The summary of review authors’ judgments about each risk
of bias item for each included study
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on lipid profiles including total- and LDL-cholesterol,
triglycerides, HDL-cholesterol, and Lp(a) at baseline and
end of intervention in both intervention and placebo
groups.
Animal or in-vitro trials, clinical trials without control
groups, no RCT design, and any trial protocols, the con-
gress abstracts without full text, and the studies did not
meet the minimum requirement for quality assessment
score were excluded from this meta-analysis.
Data extraction and quality assessment
The quality assessment and data extraction from each
included trial were conducted by two independent inves-
tigators (RT and MA), using Cochrane Collaboration risk
NOTE: Weights are from random effects analysis
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Fig. 3 A-E. Meta-analysis lipid profiles standardized mean differences estimates for (a) total cholesterol, b for LDL-cholesterol, c for triglycerides, d
for HDL-cholesterol and (e) for lipoprotein(a) in CoQ10 and control groups (CI = 95%).Total SS, total sample size
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of bias tool and standard Excel sheet-form 2008, respect-
ively. Any disagreement was discussed by a third investi-
gator (ZA or MV.J).
The following study characteristics were used to assess
the quality of included trials: “randomization generation,
allocation concealment, blinding of participants and out-
come assessors, incomplete outcome data, selective out-
come reporting, and other sources of bias”. The
following data was extracted from each clinical trial: first
author’s name, year of publication, mean age, country of
origin, study design, sample size (in intervention and
placebo groups), duration of trial, dose of supplement,
type of treatment and placebo in both intervention and
control groups, the mean and SD/or 95% CI for total-
and LDL-cholesterol, triglycerides, HDL-cholesterol,
lipoprotein (a) concentrations at baseline and end of
intervention in both intervention groups.
Statistical analyses
All statistical analyses were conducted using STATA ver-
sion 12.0 (Stata Corp, College Station, TX) and Review
Manager V.5.3 software (Cochrane Collaboration, Ox-
ford, UK). The Cochran (Q) and I-squared statistics (I2)
were applied to show the heterogeneity among included
trials. Upon existing heterogeneity across trials (I2 ≥ 50%
with P < 0.05), random effects model with DerSimonian
and Laird method; otherwise, fixed-effect model with in-
verse variance method were used to calculate the stan-
dardized mean differences (SMDs) with 95% CI
considering as the pool effect size. Further, subgroup
analyses were used based on pre-defined criteria such as
type of disease (HF vs. CAD), type of intervention (Q10
vs. Q10 plus other nutrients), dosage of supplement (≤
150 vs. > 150 mg/day), duration of trial (< 8 weeks vs.
≥8 weeks), and sample size (≤50 vs. > 50 individuals in
intervention groups) to identify the source of heterogen-
eity based on confounding variables.
Sensitivity analyses were conducted to specify the ef-
fect of each included trial on the pooled SMDs, using
leave-one-out method. Egger’s and Begg’s tests were
used to indicate the potential publication bias for the
outcome measures. P < 0.05 was considered as statisti-
cally significant.
Results
A total of 814 studies were identified though our initial
literatures search. After screening RCTs, 8 studies were
determined to be appropriate for in the present
meta-analysis. The flow diagram of step by step studies
identification and selection has been illustrated in Fig. 1.
Seven clinical trials had double-blinded design and one
of the trials was single-blinded. Seven trials were con-
ducted using parallel design and one cross-over design.
Eight RCTs reported the effects of CoQ10 supplementa-
tion on total cholesterol, 6 on LDL-cholesterol, 4 on tri-
glycerides, 5 on HDL-cholesterol, and 3 on Lp(a).
Sample size varied from 21 to 73 participants with an
overall number of 267 subjects. The sample size in the
placebo group was ranged from 21 to 71 with an overall
number of 259 subjects. Duration of the intervention
Table 2 Estimation of the effects of CoQ10 supplementation on lipid profiles at baseline and the end of the treatment between
intervention and placebo groups
Variable Number
of study
Standardized
Mean
difference
CI 95% P-value Heterogeneity
I2 (%) Q P-value Heterogeneity
TC Intervention group (after vs. before) 7 -1.07 −1.88, − 0.26 0.009 93.7 95.40 < 0.001
Placebo group (after vs. before) 7 −0.37 − 0.56, − 0.19 < 0.001 42.0 10.34 0.11
Change intervention group vs. placebo group 8 −1.07 −1.94, − 0.21 0.015 94.9 138.32 < 0.001
LDL-C Intervention group (after vs. before) 5 −0.71 −1.30, − 0.12 0.019 84.8 26.27 < 0.001
Placebo group (after vs. before) 5 −0.55 −1.21, 0.10 0.098 87.3 31.60 < 0.001
Change intervention group vs. placebo group 6 −0.37 −0.87, 0.13 0.149 82.8 29.05 < 0.001
TG Intervention group (after vs. before) 3 0.15 −0.38, 0.68 0.591 71.6 7.04 0.03
Placebo group (after vs. before) 3 −0.09 −0.34, 0.17 0.493 0.00 0.31 0.85
Change intervention group vs. placebo group 4 0.01 −0.22, 0.24 0.940 0.00 2.93 0.40
HDL-C Intervention group (after vs. before) 4 0.54 −0.07, 1.16 0.081 82.3 16.93 0.001
Placebo group (after vs. before) 4 −0.01 − 0.24, 0.23 0.964 0.00 0.35 0.95
Change intervention group vs. placebo group 5 1.30 0.20, 2.41 0.021 94.7 76.05 < 0.001
Lp(a) Intervention group (after vs. before) 2 − 0.71 − 1.91, 0.50 0.252 89.1 9.19 0.002
Placebo group (after vs. before) 2 0.02 −0.37, 0.40 0.929 0.00 0.17 0.68
Change intervention group vs. placebo group 3 −1.12 −2.84, 0.61 0.204 95.7 46.96 < 0.001
HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein (a); TC total cholesterol, TG triglycerides
Jorat et al. Lipids in Health and Disease  (2018) 17:230 Page 5 of 9
among included trials was ranged from 4 to 48 weeks.
The detailed characteristics of included trials were sum-
marized in Table 1. The assessment of the methodo-
logical quality of the included trials has been indicated
in Fig. 2. The findings of risk of bias assessment indi-
cated that 6 studies were at unclear risk of bias, and 2
studies were at high risk bias based on the judgments of
author.
Effects of CoQ10 on lipid profiles
Using random-effect model, the pooled results for lipid
profiles showed that CoQ10 supplementation signifi-
cantly decreased total cholesterol (SMD -1.07; 95% CI,
− 1.94, − 0.21, P = 0.01; I2 = 94.9%) and increased
HDL-cholesterol levels (SMD 1.30; 95% CI, 0.20, 2.41, P
= 0.02; I2 = 94.7%). We found no significant impact of
CoQ10 supplementation on LDL-cholesterol (SMD
-0.37; 95% CI, − 0.87, 0.13, P = 0.14; I2 = 82.8%) and
Lp(a) (SMD -1.12; 95% CI, − 2.84, 0.61, P = 0.20; I2 =
95.7%), using random-effect model and triglycerides
levels (SMD 0.01; 95% CI, − 0.22, 0.24, P = 0.940; I2 =
0.00%), using fixed-effect model (Fig. 3).
The detailed results of meta-analyses for the effects of
CoQ10 on lipid profiles including total- and LDL-chol-
esterol, triglycerides, HDL-cholesterol, lipoprotein(a)
concentrations at baseline and end of the trial in both
intervention and placebo groups have been presented in
Table 2.
The findings of sensitivity analyses revealed that pooled
SMDs for the impact of CoQ10 on LDL-cholesterol and
triglycerides were robust, and removing each trial did not
affect the overall results of meta-analysis. Further, the
pooled SMDs for total cholesterol was significantly differ-
ent between the pre- (− 1.07; 95% CI, − 1.94, − 0.21) and
post-sensitivity pooled SMD (− 0.26; 95% CI, − 0.72, 0.18)
after removing Sharifi et al. [13]. For HDL-cholesterol
also, the pre- (1.30; 95% CI, 0.20, 2.41) and post-sensitivity
pooled SMD were significantly different after excluding
Singh et al. [14] (1.41; 95% CI, − 0.20, 3.03) and Mohseni
et al. [15] (0.47; 95% CI, − 0.13, 1.09) (Table 3).
Considering type of disease, the results of subgroup ana-
lysis showed a significant reduction in total cholesterol
concentrations among patients with CAD (SMD -2.01;
95% CI, − 3.43, − 0.60) rather than those with HF (SMD
0.16; 95% CI, − 0.15, 0.47). Trials applying dosages
≤150 mg/day indicated greater reduction in total choles-
terol levels (SMD -1.53; 95% CI, − 2.83, − 0.23) compared
with the dosage of intervention > 150 mg/day (SMD -0.52;
95% CI, − 1.78, 0.73). Moreover, compared with trials
shorter than 8 weeks, total cholesterol concentrations
showed greater reduction in trials with ≥8 weeks’ supple-
mentation (0.06 vs. -1.94, 95% CI: -3.33, − 0.54) (Table 4).
LDL-cholesterol and Lp(a) levels did not show any signifi-
cant difference applying potential moderators in subgroup
analyses (Table 4).
CoQ10 supplementation significantly increased
HDL-cholesterol concentrations in patients with CVD
(SMD 2.28; 95% CI, 0.51, 4.05) rather than those with
HF (SMD -0.04; 95% CI, − 0.43, 0.36). Considering
the dosage of intervention, subgroup analysis revealed
that CoQ10 doses ≤150 mg/day significantly increased
HDL-cholesterol concentrations (SMD 0.66; 95% CI,
0.03, 1.30) rather than doses of > 150 mg/day inter-
vention (SMD 2.58; 95% CI, − 2.65, 7.81). Further,
with the total sample size > 50 participants,
HDL-cholesterol levels were significantly higher (SMD
2.00; 95% CI, 0.06, 3.93) when compared to trials
with ≤50 participants (SMD 0.41; 95% CI, − 0.39,
Table 3 The assess of contribution each clinical trials in association between CoQ10 supplementation and lipid profiles based on
sensitivity analysis
Variable Pre-sensitivity analysis Upper
&
lower
of
effect
size
Post-sensitivity analysis
No. of studies included Pooled SMD (random effect) 95% CI Pooled SMD (random effect) 95% CI Excluded studies
TC 8 −1.07 − 1.94, − 0.21 Upper −0.26 − 0.72, 0.18 Sharifi (b)
Lower −1.30 −2.29, −0.31 Dai Y
LDL-C 6 −0.37 −0.87, 0.13 Upper −0.14 − 0.42, 0.12 Pourmoghaddas
Lower −0.48 − 1.04, 0.06 Belardinelli
TG 4 0.01 −0.22, 0.24 Upper 0.16 −0.15, 0.48 Singh (2003)
Lower −0.05 − 0.30, 0.19 Belardinelli
HDL-C 5 1.30 0.20, 2.41 Upper 1.67 0.32, 3.03 Dai Y
Lower 0.47 −0.13, 1.09 Mohseni
Lp(a) 3 −1.12 −2.84, 0.61 Upper − 0.03 −0.39, 0.33 Singh (1999)
Lower −1.79 −4.98, 1.40 Manolescu
HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein (a); TC total cholesterol, TG triglycerides
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1.20). The detailed results of subgroup analyses have
been summarized in Table 4.
Publication bias
Begg’s and Egger’s statistics indicated no significant evi-
dence of publication bias for the meta-analyses evaluat-
ing the effects of CoQ10 on total cholesterol (Begg’s: Z
= − 0.99, P = 0.32 and Egger’s: B = − 8.96, P = 0.05),
LDL-cholesterol (Begg’s: Z = 0.19, P = 0.85 and Egger’s:
B = − 0.51, P = 0.91), triglycerides (Begg’s: Z = 1.07, P =
0.08 and Egger’s: B = 2.99, P = 0.10), HDL-cholesterol
(Begg’s: Z = 0.49, P = 0.62 and Egger’s: B = 5.31, P = 0.43),
and Lp (a) (Begg’s: Z = 0.52, P = 0.60 and Egger’s: B = −
7.28, P = 0.50).
Discussion
The findings of current systematic review and
meta-analysis showed that CoQ10 supplementation
Table 4 The effects of CoQ10 supplementation on lipid profiles
with CI 95% by using subgroup analysis
Variables Ka I2 (%) Q test SMD (95% CI) P-value
TC
Total 8 94.9 138.32 −1.07 (−1.94, −0.21) 0.015
Type of disease
HF 3 0.00 0.04 0.16 (−0.15, 0.47) 0.306
CAD 5 96.7 122.87 −2.01 (−3.43, −0.60) 0.005
Type of intervention
Q10 6 84.7 32.72 −0.32 (−0.85, 0.22) 0.244
Q10 + other 2 99.0 102.67 −4.50 (−13.39, 4.39) 0.321
Dosage of intervention (mg/dL)
≤ 150 5 96.3 107.92 −1.53 (−2.83, −0.23) 0.021
> 150 3 93.4 30.37 −0.52 (−1.78, 0.73) 0.414
Duration of study
< 8 weeks 3 0.00 1.06 0.06 (−0.26, 0.39) 0.707
≥ 8 weeks 5 96.9 128.76 −1.94 (−3.33, − 0.54) 0.006
Sample size
≤ 50 person 2 0.00 0.60 −0.03 (− 0.44, 0.39) 0.13
> 50 person 6 96.3 135.05 −1.52 (−2.67, − 0.37) 2.59
LDL-C
Total 6 82.8 29.05 −0.37 (− 0.87, 0.13) 0.149
Type of disease
HF 3 91.8 24.47 −0.51 (−1.66, 0.64) 0.387
CAD 3 42.7 3.49 −0.25 (− 0.61, 0.11) 0.167
Type of intervention
Q10 6 82.8 29.05 −0.37 (− 0.87, 0.13) 0.149
Q10 + other – – – – –
Dosage of intervention
≤ 150 3 48.7 3.90 −0.24 (− 0.64, 0.16) 0.232
> 150 3 91.8 24.25 −0.53 (−1.64, 0.57) 0.344
Duration of study
< 8 weeks 3 40.5 3.36 −0.12 (− 0.55, 0.30) 0.568
≥ 8 weeks 3 91.2 22.64 −0.62 (−1.55, 0.31) 0.195
Sample size
≤ 50 person 2 70.0 3.33 −0.14 (− 0.91, 0.63) 0.721
> 50 person 4 87.8 24.52 −0.48 (−1.17, 0.21) 0.171
HDL-C
Total
Type of disease 5 94.7 76.05 1.30 (0.20, 2.41) 0.021
HF 2 0.00 0.02 −0.04 (−0.43, 0.36) 0.859
CAD 3 95.9 48.48 2.28 (0.51, 4.05) 0.011
Type of intervention
Q10 5 94.7 76.05 1.30 (0.20, 2.41) 0.021
Q10 + other – – – – –
Dosage of intervention
Table 4 The effects of CoQ10 supplementation on lipid profiles
with CI 95% by using subgroup analysis (Continued)
Variables Ka I2 (%) Q test SMD (95% CI) P-value
≤ 150 3 78.5 9.29 0.66 (0.03, 1.30) 0.041
> 150 2 98.5 66.76 2.58 (−2.65, 7.81) 0.334
Duration of study
< 8 weeks 3 62.7 5.36 0.24 (−0.30, 0.78) 0.387
≥ 8 weeks 2 97.8 45.29 3.14 (−0.96, 7.24) 0.133
Sample size
≤ 50 person 2 71.2 3.48 0.41 (−0.39, 1.20) 0.315
> 50 person 3 97.0 67.48 2.00 (0.06, 3.93) 0.043
Lp(a)
Total 3 95.7 46.96 −1.12 (−2.84, 0.61) 0.204
Type of disease
HF 1 – 0.00 0.13 (−0.39, 0.66) 0.621
CAD 2 97.3 37.38 −1.79 (−4.98, 1.40) 0.272
Type of intervention
Q10 3 95.7 46.96 −1.12 (−2.84, 0.61) 0.204
Q10 + other – – – – –
Dosage of intervention
≤ 150 2 97.3 37.38 −1.79 (− 4.98, 1.40) 0.272
> 150 1 – 0.00 0.13 (−0.39, 0.66) 0.621
Duration of study
< 8 weeks 2 97.7 44.27 −1.64 (−5.14, 1.87) 0.360
≥ 8 weeks 1 – 0.00 −0.18 (− 0.69, 0.32) 0.476
Sample size
≤ 50 person 1 – 0.00 −3.44 (−4.36, −2.53) < 0.001
> 50 person 2 0.00 0.72 −0.03 (− 0.40, 0.33) 0.866
a K, Number of SMD included; CAD coronary artery disease, HDL-C high density
lipoprotein-cholesterol, HF heart failure, LDL-C low density lipoprotein-
cholesterol, Lp(a) Lipoprotein(a), TC total cholesterol
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significantly improved lipid profiles by decreasing total
cholesterol and increasing HDL-cholesterol levels,
though did not affect triglycerides, LDL-cholesterol and
Lp(a) levels in patients with CAD.
CoQ10 deficiency usually occurs with aging and may
increase the risk of CVD [9, 16, 17]. We have previously
demonstrated in another meta-analysis that taking
CoQ10 by patients with metabolic disorders significantly
reduced serum triglycerides levels, yet did not affect
other lipid profiles [10]. Meta-analysis conducted by
Pirro et al. [18] showed that taking a nutraceutical com-
bination of red yeast rice, berberine, policosanol, astax-
anthin, CoQ10 and folic acid significantly reduced
serum triglycerides, total-, LDL-and HDL-cholesterol
levels. Supplementation with 200 mg/day CoQ10 for
12 weeks significantly increased HDL-cholesterol levels
in hyperlipidemic patients with myocardial infarction,
though did not affect other parameters of lipid profiles
[15]. Supplementation with 120 mg/day CoQ10 for
28 days led to similar results among patients with acute
coronary disease [19]. In a meta-analysis conducted by
Suksomboon et al. [12], total cholesterol levels signifi-
cantly decreased after taking CoQ10 plus fenofibrate.
The anti-hyperlipidemic effect of fenofibrate has already
been proven; though its synergistic impact with CoQ10
is promising. Significant reduction in serum triglyceride
levels was reported following supplementation with
CoQ10 plus fenofibrate [12]. However, Sahebkar et al.
[11] documented in their meta-analysis that CoQ10 sup-
plementation significantly decreased plasma Lp(a) levels
in individuals with lipoprotein a [Lp(a)] ≥30 mg/dL,
though other lipid profiles parameters remained un-
changed. In addition, CoQ10 administration to diabetic
patients had no beneficial effects on lipid profiles and
blood pressure [12].
The type and different dosages of CoQ10 used are some
of the possible reasons that might explain the discrepant
results among previous published studies. Although the
main reason CoQ10 affects lipid profiles is unknown; sev-
eral mechanisms have been proposed by which CoQ10
supplements could improve lipid profiles. As an intracel-
lular antioxidant, CoQ10 protects the cell membrane
phospholipids and mitochondrial membrane protein
against free radical-induced damage [6]. Aldehyde deriva-
tives from lipid peroxidation, such as malondialdehyde, in-
hibit lecithin-cholesterol acyl transferase (LCAT), which
esterifies free cholesterol on HDL-cholesterol. So, CoQ10
can promote HDL-cholesterol production, suppress oxida-
tive stress and subsequently reduce malondialdehyde
levels [20]. In addition, CoQ10 ingestion may induce gene
expression of peroxisome proliferator-activated receptor-γ
(PPAR-γ) through activating calcium-mediated AMPK
pathway and inhibiting differentiation-induced adipogene-
sis [21]. PPAR-γ is a nuclear receptor protein which acts
as a ligand-activated transcription factor in regulating
gene expression affecting insulin and lipid metabol-
ism, differentiation, proliferation, survival and inflam-
mation [22].
Conclusions
CoQ10 supplementation significantly improved some
of the parameters of lipid profile including total chol-
esterol and HDL-cholesterol levels in patients with
CAD, though it might not affect the other parameters
of lipid profiles. Additional prospective studies regard-
ing the effect of CoQ10 intake on lipid profiles in pa-
tients with CAD are necessary.
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